Interested in the very latest research and treatment options for viral hepatitis? The Liver Meeting® in Washington DC on October 20-24 should be on your fall education travel list. Register today to take advantage of the comprehensive coverage of hepatitis on slate in this year’s program.
Two Special Interest Groups (SIGs) have innovative programs planned. The Hepatitis C SIG program on Friday, October 20, will focus on treatment for the hepatitis C patient who injects drugs, and is designed to provide clinicians, public and global health experts and patient advocates with the skills and information needed to improve the cascade of care in this “difficult to reach” population. The SIG will host a second symposium on Monday, October 23, focused on reviewing the latest approved regimens and how they will help the most challenging patients. Emphasis will be on clinical knowledge and application to individual patient management decisions, the AASLD-IDSA Guidance Panel treatment recommendations, and global perspectives on disease eradication strategies.
The Hepatitis B SIG program, on Friday, October 20, will look at the critical need for a curative therapy for HBV, the challenges of developing new therapies and where new therapies will fit in treatment plans of the further.
During the always popular Hepatology Debrief, on Tuesday, Oct. 24, Paul Y. Kwo, MD, FAASLD, a noted hepatitis C expert, will synthesize all of the most promising data on treating viral hepatitis presented throughout The Liver Meeting® in one rapid fire comprehensive session.
There will also be numerous parallel sessions on October 22 and 23, posters dedicated to the latest research and treatment options, and a Presidential Plenary on October 24 dedicated to viral hepatitis.
Don’t miss the opportunity to register early for the Meet-the-Professor Luncheons on Saturday, October 21 and the Early Morning Workshops on Saturday through Monday. Viral hepatitis presentations will address such topics as resistance to treatment, emerging therapies for hepatitis B and hepatitis C in special populations.